In addition, our findings revealed that methylation of SOX17 promoter in ctDNA is associated with unfavorable prognosis in patients with metastatic breast cancer and that in patients with early breast cancer, methylation of SOX17 promoter in the EpCAM-positive CTC-fraction is associated with decreased DFI. This evidence concerns the gene SOX17 and breast carcinoma.